The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the future
Abstract
Incretin‐based therapies, such as the injectable glucagon‐like peptide‐1 (GLP‐1) receptor agonists and orally administered dipeptidyl peptidase‐4 (DPP‐4) inhibitors, have recently been introduced into clinical practice. At present, the GLP‐1 receptor agonists need to be administered once or twice daily. Several once‐weekly GLP‐1 receptor agonists are in phase 3 development. This review examines the efficacy, safety and perspective for the future of the once‐weekly GLP‐1 receptor agonists: exenatide once weekly, taspoglutide, albiglutide, LY2189265 and CJC‐1134‐PC, and compared them to the currently available agonists, exenatide BID and liraglutide QD. A greater reduction in haemoglobin A1c (HbA1c) and fasting plasma glucose was found with the once‐weekly GLP‐1 receptor agonists compared with exenatide BID, while the effect on postprandial hyperglycaemia was modest with the once‐weekly GLP‐1 receptor agonist. The reduction in HbA1c was in most studies greater compared to oral antidiabetic drugs and insulin glargine. The reduction in weight did not differ between the short‐ and long‐acting agonists. The gastrointestinal side effects were less with the once‐weekly agonists compared with exenatide BID, except for taspoglutide. Antibodies seem to be most frequent with exenatide once weekly, while hypersensitivity has been described in few patients treated with taspoglutide. Injection site reactions differ among the long‐acting GLP‐1 receptor agonists and are observed more frequently than with exenatide BID and liraglutide. In humans, no signal has been found indicating an association between the once‐weekly agonists and C‐cell cancer. The cardiovascular safety, durability of glucose control and effect on weight will emerge from several ongoing major long‐term trials. The once‐weekly GLP‐1 receptor analogues are promising candidates for the treatment of type 2 diabetes, although their efficacy may not be superior to once‐daily analogue liraglutide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Self-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Research works printed but not linked: 74
- 10.2337/diacare.27.5.1047 · DOI · Paper page
- 10.1007/s00125-010-1684-1 · DOI · Paper page
- 10.1152/physrev.00034.2006 · DOI · Paper page
- 10.1136/bmj.b1668 · DOI
- Bhattacharyya OK, 2009, Update on the Canadian Diabetes Association 2008 clinical practice guidelines., Can Fam Physician, 55, 39
- 10.4158/EP.15.6.540 · DOI · Paper page
- 10.1007/s00125-010-1702-3 · DOI
- 10.1016/j.beem.2009.03.003 · DOI
- 10.1097/MCO.0b013e328302f414 · DOI
- 10.1016/j.beem.2009.03.008 · DOI
- 10.1001/jama.298.2.194 · DOI · Paper page
- 10.7326/0003-4819-147-6-200709180-00178 · DOI · Paper page
- 10.1016/j.molmed.2008.01.003 · DOI · Paper page
- 10.2337/dc09-S315 · DOI · Paper page
- Nauck MA, 1997, Glucagon‐like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans., Am J Physiol, 273, E981
- 10.1210/jc.80.3.952 · DOI · Paper page
- 10.2337/diab.44.9.1126 · DOI · Paper page
- 10.1016/S0928-0987(03)00073-3 · DOI
- 10.2165/00003495-200767060-00008 · DOI
- 10.1177/0091270006288215 · DOI
- Eng J, 1992, Isolation and characterization of exendin‐4, an exendin‐3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas., J Biol Chem, 267, 7402, 10.1016/S0021-9258(18)42531-8 · DOI · Paper page
- 10.1093/ajhp/62.2.173 · DOI · Paper page
- 10.1046/j.1464-5491.2001.00424.x · DOI
- 10.2337/dc09-2260 · DOI · Paper page
- Vaag A, 2008, Liraglutide, a human GLP‐1 analogue, substantially reduces HbA(1c) in subjects with type 2 diabetes, irrespective of HbA(1c) at baseline., Diabetologia, 51, S68
- Buse J, 2010, The incidence of antibody formation and the levels of antibodies are lower with liraglutide than exenatide in a head‐to‐head comparison., Diabetologia, 53, S341.
- 10.2337/dc06-2375 · DOI · Paper page
- 10.1016/S0142-9612(99)00002-2 · DOI · Paper page
- 10.2337/dc09-1914 · DOI · Paper page
- Knudsen LB, 2010, Liraglutide: short lived effect on gastric emptying‐long lasting effects on body‐weight., Diabetes, 59, A161.
- 10.1111/j.1464-5491.2009.02752.x · DOI
- 10.1016/S0140-6736(10)60590-9 · DOI · Paper page
- 10.1016/S0140-6736(10)60307-8 · DOI · Paper page
- 10.1016/S0140-6736(10)60406-0 · DOI · Paper page
- Pullman J, 2010, DURATION‐5: exenatide once weekly resulted in significantly greater improvement in glycaemic control than exenatide twice daily in patients with type 2 diabetes., Diabetologia, 53, S336.
- Linnebjerg H, 2009, The effect of exenatide on QTc interval in healthy subjects., Diabetes, 58, A161.
- 10.1210/en.2009-1459 · DOI
- Uhles S, 2010, Taspoglutide, a novel human once‐weekly GLP‐1 analogue, improves beta‐cell survival in ZDF rats., Diabetes, 59, A148.
- Pellanda C, 2010, Effect of taspoglutide, a human GLP‐1 analog, on insulin secretion in patients (pts) with type 2 diabetes (T2D)., Diabetes, 59, A160
- 10.2337/dc08-1961 · DOI
- 10.1111/j.1464-5491.2010.02990.x · DOI
- Kapitza C, 2006, BIM51077, a novel GLP‐1 analog, achieves sustained improvement in blood glucose control over 28 days of treatment., Diabetes, 55, A119.
- Raz I, 2010, Taspoglutide, a once‐weekly human GLP‐1 analog, as monotherapy significantly lowers A1c and body weight in patients with type 2 diabetes (T2D): results from the T‐emerge 1 phase 3 trial., Diabetes, 59, A107.
- Rosenstock J, 2010, Superior glycemic control with taspoglutide, a once‐weekly human GLP‐1 analog, compared with twice daily exenatide in type 2 diabetes (T2DM) inadequately controlled on oral agents: the T‐emerge 2 trial., Diabetes, 59, A17.
- Rosenstock J, 2010, Taspoglutide, a once‐weekly human GLP‐1 analog, improves glucose tolerance and insulin secretion in patients with type 2 diabetes (T2DM): results of a meal tolerance test from T‐emerge 2., Diabetes, 59, A196.
- Bergenstal R, 2010, Once weekly taspoglutide, a human GLP‐1 analog, is superior to sitagliptin in improving glycemic control and weight loss in patients with type 2 diabetes (T2D): results from the T‐emerge 4 trial., Diabetes, 59, A16.
- Nauck M, 2010, Taspoglutide, a once‐weekly human GLP‐1 analog, provides comparable glycemic control to insulin glargine,’ with superior weight loss and less hypoglycemia in type 2 diabetes (T2D): a phase 3, open‐label trial (T‐emerge 5)., Diabetes, 59, A16.
- Hollander P, 2010, Once‐weekly taspoglutide, a human GLP‐1 analog, is superior to placebo in improving glycemic control and body weight loss in obese patients with type 2 diabetes (T2D) inadequately controlled with metformin monotherapy: results from the T‐emerge 7 trial., Diabetes, 59, A160.
- 10.1111/j.1463-1326.2008.00992.x · DOI · Paper page
- 10.1007/s001250050903 · DOI · Paper page
- Bloom M, 2003, Albugon (TM) fusion protein: a long‐acting analog of GLP‐1 that provides lasting antidiabetic effect in animals., Diabetes, 52, A112.
- Matthews D, 2008, Liraglutide, a once‐daily human GLP‐1 analog, significantly improves beta‐cell function in subjects with type 2 diabetes., Diabetes, 57, A150
- 10.2337/dc09-0366 · DOI · Paper page
- 10.1002/dmrr.1080 · DOI · Paper page
- Umpierrez G, 2009, The effect of LY2189265 (GLP‐1 analogue) once weekly on HbA(1c) and beta cell function in uncontrolled type 2 diabetes mellitus: the EGO study analysis., Diabetologia, 52, S59.
- Thibaudeau K, 2006, CJC‐1134‐PC: an exendin‐4 conjugate with extended pharmacodynamic profiles in rodents., Diabetes, 55, A103.
- 10.1053/j.gastro.2008.01.017 · DOI · Paper page
- 10.2337/db07-0092 · doi:10.2337/db07-0092
- Wang M, 2009, PC‐DAC (TM): exendin‐4 (CJC‐1134‐PC) significantly reduces HbA1c and body weight as an adjunct therapy to metformin: two randomized, double‐blind, placebo‐controlled, 12 week, phase II studies in patients with type 2 diabetes mellitus., Diabetes, 58, A148.
- 10.1023/A:1015396825274 · DOI · Paper page
- 10.1016/j.brainres.2005.03.011 · DOI · Paper page
- Imeryuz N, 1997, Glucagon‐like peptide‐1 inhibits gastric emptying via vagal afferent‐mediated central mechanisms., Am J Physiol, 273, G920
- 10.1016/S0140-6736(08)61247-7 · DOI
- 10.1056/NEJMp1001578 · DOI · Paper page
- 10.1002/cncr.22244 · DOI · Paper page
- 10.1185/03007990902820519 · DOI · Paper page
- 10.2337/dc10-0482 · DOI · Paper page
- 10.1111/j.1463-1326.2010.01231.x · DOI · Paper page
- Bloomgren G, 2010, Incidence and relative incidence of medical record confirmed acute pancreatitis: exenatide initiators compared to other antidiabetic drug initiators., Diabetes, 59, A147
- 10.1111/j.1476-5381.2009.00376.x · DOI
- Shen L, 2009, Cardiovascular safety of exenatide BID: an integrated‐analysis from long‐term controlled clinical trials in subjects with type 2 diabetes., Diabetologia, 52, S298.
- Gabber A, 2010, The effect of diabetes duration on the response to liraglutide and glimepiride in type 2 diabetes., Diabetes, 59, A197.
- 10.1016/S0140-6736(10)60407-2 · DOI · Paper page
- 10.2337/dc10-0612 · DOI · Paper page
Cited by
Impact of albumin on drug delivery — New applications on the horizon
Elsadek, B., & Kratz, F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.069 · Cited by 832
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Ahrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495
Metadata
- Authors
- Madsbad, S., Kielgast, U., Asmar, M., Deacon, C. F., Torekov, S. S., & Holst, J. J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-03-24
- Volume
- 13
- Issue
- 5
- Pages
- 394-407
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2118805427
- Cited by
- 202
- References
- 14
- FWCI
- 21.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the future. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01357.x
- The paper
- Madsbad, S., Kielgast, U., Asmar, M., Deacon, C. F., Torekov, S. S., & Holst, J. J. (2011). An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the future. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01357.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.